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Abstract. Apoptosis and oxidative stress are essential 
for the pathogenesis of acute liver failure and fulminant 
hepatic failure. Human placental hydrolysate (hPH) has 
been reported to possess antioxidant and anti‑inflammatory 
properties. In the present study, the protective effects of hPH 
against d-galactosamine (d-GalN)- and lipopolysaccha-
ride (LPS)-induced hepatocyte apoptosis were investigated 
in vivo. In addition, the molecular mechanisms underlying the 
anti-apoptotic activities of hPH against d-GalN-induced cell 
death in vitro were examined. Male Sprague-dawley rats were 
injected with d-GaIN/LPS with or without the administration 
of hPH. Rats were sacrificed 24 h after D‑GaIN/LPS intraperi-
toneal injection, and the blood and liver samples were collected 
for future inflammation and hepatotoxicity analyses. Changes 
in cell viability, apoptosis protein expression, mitochondrial 
mass, mitochondrial membrane potential, reactive oxygen 
species generation, and the levels of proteins and mRNA 
associated with a protective mechanism were determined in 
HepG2 cells pretreated with hPH for 2 h prior to d-GalN 
exposure. The findings suggested that hPH treatment effectively 
protected against d-GalN/LPS-induced hepatocyte apoptosis 
by reducing the levels of alanine aminotransferase, aspartate 
aminotransferase, lactate dehydrogenase, interleukin-6, and 
tumor necrosis factor-α, and increasing the level of prolifer-
ating cell nuclear antigen. It was also found that hPH inhibited 
the apoptotic cell death induced by d-GalN. hPH activated 
the expression of antioxidant enzymes, including superoxide 
dismutase, glutathione peroxidase, and catalase, which were 
further upregulated by the Kelch-like EcH2-associated 
protein 1-p62-nuclear factor-erythroid 2-related factor 2 
pathway, a component of oxidative stress defense mechanisms. 
Furthermore, hPH markedly reduced cytosolic and mitochon-
drial reactive oxygen species and rescued mitochondrial loss 
and dysfunction through the reduction of damage-regulated 
autophagy modulator, p53, and c/EBP homologous protein. 
collectively, hPH exhibited a protective role in hepatocyte 
apoptosis by inhibiting oxidative stress and maintaining cell 
homeostasis. The underlying mechanisms may be associated 
with the inhibition of endoplasmic reticulum stress and mini-
mization of the autophagy progress.
Introduction
Acute liver failure (ALF), sometimes referred to as fulminant 
hepatic failure, is a severe liver disease characterized by 
coagulopathy and liver inflammation in patients with previ-
ously normal liver function (1). The onset of liver injury, often 
accompanied by endotoxemia and hepatocyte death, can result 
in high mortality rates in animals and humans, due to the lack 
of an effective therapy for ALF, other than liver transplanta-
tion (2).
The administration of d-galactosamine (d-GalN) and 
lipopolysaccharides (LPS) establishes an animal model for 
ALF; it severely impairs liver function in laboratory animals, 
and can be used to investigate ALF (3). LPS, a type of endo-
toxin, can cause liver tissue damage through activation of 
inflammatory cytokines, including interleukin (IL)‑1β, IL-6, 
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tumor necrosis factor (TNF)-α, and interferon-γ (4). A report 
suggests that LPS as an inflammatory mediator can stimulate 
the production of reactive oxygen species (ROS) and can 
be used broadly to induce research models of ALF (5). A 
d-GalN/LPS-induced animal model of ALF is representative 
of human liver failure and has been widely used to investigate 
mechanisms and potential therapeutic drugs for clinical use in 
treating ALF (2). Increasing evidence has shown that oxidative 
stress and hepatocyte apoptosis are two important pathogenic 
factors that contribute to d-GalN/LPS-induced ALF (6,7).
T he  eva luat ion  of  mecha n isms i nvolved  i n 
d-GalN/LPS-induced hepatic apoptosis has indicated that 
mitochondria are critical targets for drug toxicity through the 
formation of reactive metabolites (8,9). In response to oxida-
tive stress, the cellular machinery of the antioxidative response 
is mediated by cytoprotective enzymes in the liver. When it to 
comes to oxidation, nuclear factor-E2-related factor 2 (Nrf2), 
a key sensor in antioxidative stress systems, regulates cellular 
defense against oxidative damage (10), contributing to diverse 
cellular functions, including proliferation, inflammation and 
lipid synthesis (11). The aberrant expression or function of Nrf2 
has been linked to pathologies, including hepatic steatosis (12) 
and diabetic nephropathy (13). Although Nrf2 is regularly 
sequestered by Kelch-like EcH2-associated protein 1 (Keap1) 
in the cytoplasm (14), when activated, it translocates into 
the nucleus and upregulates antioxidant response element 
(ARE) genes, including superoxide dismutase (SOd)1/SOd2, 
catalase, glutamate-cysteine ligase catalytic subunit (GcLc), 
glutamate-cysteine ligase regulatory subunit (GcLM), heme 
oxygenase-1 (HO-1), cytochrome P450s, multidrug-resis-
tant proteins and NAd(P)H dehydrogenase quinone 1 
(NQO1) (15,16).
In general, the autophagy-dependent degradation of 
impaired organelles, including the selective degradation of 
the endoplasmic reticulum (ER; reticulophagy), mitochon-
dria (mitophagy), and lipid droplets (lipophagy), is a crucial 
cellular pathway for maintaining cell homeostasis (17,18). 
However, autophagy is also regarded as a pro-apoptotic factor 
and causes ‘type II’ programmed cell death (19). The cellular 
damage mediated by p53 has a pathological role in the progres-
sion of hepatosteatosis. It is noteworthy that p53 can promote 
the expression of damage-regulated autophagy modulator 
(dRAM), an inducer of autophagy-mediated apoptosis (20). 
Previous studies have revealed that human placental 
hydrolysate (hPH) is a rich source of various bioactive 
substances, including polydeoxyribonucleotides, RNA, dNA, 
peptides, amino acids, enzymes, and trace elements, among 
others (21). Human placenta has been demonstrated to possess 
various therapeutic properties ranging from wound healing 
to immunomodulation (22). The use of aqueous extract of 
human placenta in wound healing, ophthalmology, infertility, 
apoplexy, and epilepsy has evolved from folk knowledge to 
modern scientific practice (23). In a previous clinical trial, it 
was identified that treatment of hPH ameliorated alcoholic or 
nonalcoholic steatohepatitis in patients (24,25). In addition, 
hPH has been shown to have a protective effect in ALF via 
an anti‑inflammatory response (26). However, the mechanism 
underlying this anti-apoptotic action and the defense mecha-
nism remain to be fully elucidated. Given the various uses 
of human placenta for intervention in different diseases, the 
present study was undertaken to investigate the protective 
effects of hPH against apoptotic hepatocyte cell death in vivo 
and in vitro.
Materials and methods
Reagents and antibodies. All chemicals and solvents used 
were of the highest analytical grade available. cell culture 
supplies and media, including fetal bovine serum (FBS), phos-
phate-buffered saline (PBS), and penicillin-streptomycin were 
purchased from Thermo Fisher Scientific, Inc. (Waltham, MA, 
USA). The cell counting Kit-8 (ccK-8; cat. no. cK04-11) 
was from dojindo Molecular Laboratories, Inc. (Kumamoto, 
Japan). Protease inhibitor cocktail (cat. no. P8340) and 
d-GalN (cat. no. G0500) were purchased from Sigma-Aldrich; 
EMd Millipore (Billerica, MA, USA). Anti-proliferating 
cell nuclear antigen (PcNA; cat. no. ab15497), anti-Tomm20 
(cat. no. ab56783) and anti-Lamin B1 (cat. no. ab16048) 
antibodies were purchased from Abcam (cambridge, UK). 
Anti-poly (AdP) ribose polymerase (PARP; cat. no. 9532S) 
antibody was purchased from cell Signaling Technology, 
Inc. (Beverly, MA, USA). Anti-B-cell lymphoma 2 (BcL2; 
cat. no. Sc-7382), anti-Bcl-2-associated X protein (BAX; 
cat. no. Sc-526), anti-dRAM (cat. no. Sc-81713), anti-SOd1 
(cat. no. Sc-17767), anti-SOd2 (cat. no. Sc-130345), anti-gluta-
thione peroxidase (GPx; cat. no. Sc-133160), anti-catalase 
(cat. no. Sc-271358), anti-Keap1 (cat. no. Sc-365626), anti-HO-1 
(cat. no. Sc-136960), anti-p53 (cat. no. Sc-126), anti-GAPdH 
(cat. no. Sc-20357), and anti-Nrf2 (cat. no. Sc-81342) anti-
bodies were purchased from Santa cruz Biotechnology, Inc. 
(Santa cruz, cA, USA). Anti-microtubule-associated protein 
1A/1B-light chain 3 (Lc3)I/II (cat. no. PM036), anti-phospho-
rlyated-p62 (cat. no. PM074), and anti-p62 (cat. no. PM045) 
antibodies were purchased from MBL International 
corporation (Woburn, MA, USA). hPH (Laennec inj.) was 
manufactured by Green cross WellBeing corporation 
(Seongnam, Korea) through the hydrolysis of human placenta 
with Hcl and pepsin.
Animals and experimental design. Sprague-dawley rats (Sd) 
rats (male, 6-8 weeks old, weighing ~200-250 g each) were 
purchased from Raonbio, Inc. (Yongin, Korea). These rats 
were provided with adequate food and water ad libitum and 
were housed in clean cages for 1 week. The laboratory temper-
ature was 24±1˚C and relative humidity was 40‑80%. All 
animal experiments were performed according to the Guide 
for the care and Use of Laboratory Animals as published by 
the US National Institutes of Health. The present study was 
reviewed and approved by the Animal Welfare and Research 
Ethics committee at chung-Ang University (Seoul, Korea; 
2017-00003). Acute liver injury was induced by intraperitoneal 
injection of LPS (15 µg/kg) together with d-GalN (700 mg/kg) 
dissolved in normal saline, which can increase the sensitivity 
of hepatocytes. Blood was collected from the inferior vena cava 
24 h following injection of d-GalN/LPS. The Sd rats were 
then dissected, and liver tissues were removed immediately for 
histological detection. Normal PBS was used in control rats. 
hPH (1.2, 2.4, and 3.6 ml/kg) was injected subcutaneously into 
each mouse 24, 48, and 72 h prior to d-GalN/LPS injection. 
As a negative control, only d-GalN/LPS was injected.
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Evaluation of serum alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST). The collected blood 
samples were stored overnight at 4˚C. The serum was isolated 
the subsequent day following centrifugation at 15,928 x g 
for 10 min at 4˚C. The ALT and AST were detected using a 
Hitachi 7600 Series automatic biochemical analyzer (Hitachi, 
Ltd., Tokyo, Japan).
Enzyme‑linked immunosorbent assay (ELISA) of cytokines. 
Based on a previous study, blood was collected for measuring 
TNF-α (cat. no. 438207) and IL-6 (cat. no. 437107) at 24 h 
post-d-GalN/LPS injection. The serum was separated by 
centrifugation at 15,928 x g at 4˚C for 10 min. The cytokines 
were measured using mouse ELISA kits (BioLegend, Inc., 
San diego, cA, USA) according to the manufacturer's protocol.
Histopathological evaluation. The liver tissues were immersed 
in normal 10% neutral buffered formalin and fixed for 48 h, 
dehydrated in a series of graded ethanol, embedded in paraffin 
wax, and cut into 5-µm sections. The paraffin-embedded 
sections were stained with hematoxylin and eosin (H&E) for 
pathological analysis under a light microscope. Histological 
changes were evaluated using a point-counting method for the 
severity of hepatic injury using an ordinal scale, as previously 
described (27). Briefly, the H&E‑stained sections were evalu-
ated at x400 magnification using the point‑counting method 
for the severity of hepatic injury with an ordinal scale as 
follows: grade 0, minimal or no evidence of injury; grade 1, 
mild injury consisting of cytoplasmic vacuolation and focal 
nuclear pyknosis; grade 2, moderate to severe injury with 
extensive nuclear pyknosis, cytoplasmic hypereosinophilia, 
and loss of intercellular borders; and grade 3, severe necrosis 
with disintegration of hepatic cords, hemorrhage, and neutro-
phil infiltration.
Measurement of apoptosis via TUNEL assay. TUNEL was 
performed to analyze dNA fragmentation indicative of 
cellular apoptosis using the in situ cell death detection kit 
(cat. no. ab206386, Abcam), according to the manufacturer's 
protocol. The paraffin wax‑embedded tissue sections were 
treated with proteinase K, and endogenous peroxidase activity 
was blocked with hydrogen peroxide. The sections were 
incubated at 37˚C with the terminal TdT nucleotide mixture 
for 1 h. The reactions were then terminated, and the slides 
were rinsed with PBS. Nuclear labeling was developed with 
horseradish peroxidase and diaminobenzidine. The number of 
apoptotic cells in each slide from at least five different fields 
was analyzed using Image-Pro Plus software (version 6.0 for 
Windows; Media cybernetics, Inc., Rockville, Md, USA) with 
the assistance of a microscope (dM750; Leica Microsystems 
GmbH, Wetzlar, Germany). The number of positive cells was 
averaged for statistical analysis.
Liver immunohistochemistry. The paraffin sections were 
de-paraffinized and rehydrated. Endogenous peroxidase 
was inactivated by incubation in 0.3% hydrogen peroxide in 
absolute methanol for 30 min. The sections were incubated 
in 5% skim milk for 30 min at room temperature. Antigen 
retrieval was performed by microwave (700 W) treatment in 
10 mM citrate buffer (pH 6.0) for 15 min. The sections were 
incubated overnight at 4˚C with anti‑PCNA primary antibody 
(Abcam) at a dilution of 1:500. Following washing with PBS, 
the sections were incubated at room temperature for 30 min 
in secondary antibody (Goat Anti-Rabbit; cat. no. ab205718; 
Abcam; 1:1,000). A brown color was developed with 3 diami-
nobenzidine for 2-4 min, and the sections were then washed in 
distilled water. The number of positively stained brown nuclei 
(denoting PCNA) in each slide from at least five different fields 
was analyzed using Image-Pro Plus software (version 6.0 
for Windows) with the assistance of a microscope (dM750, 
Leica Microsystems GmbH). The number of positive cells was 
averaged for statistical analysis.
Cell culture and treatment. Human HepG2 cells, the HepG2 
(ATcc HB 8065) cells were purchased from the Korea cell 
Line Bank (Seoul, Korea), and were cultured in dulbecco's 
modified Eagle's medium (DMEM) with 10% (v/v) 
heat‑inactivated FBS and 1% penicillin and incubated in a 
humidified incubator with 5% CO2, 95% air at 37˚C. A dose 
of 5% hPH was used in the time‑course investigation of the 
induction of antioxidant enzymes by hPH. To investigate the 
protective effects of hPH and its active mechanism on HepG2 
cells challenged by d-GaIN (Sigma; EMd Millipore), the 
cells were pretreated with hPH for 2 h, stimulated with 50 mM 
D‑GaIN at 37˚C, and harvested for the indicated experiments.
Cell viability assay. The HepG2 cells, treated as described 
above, were further treated with 50 mM d-GalN and incu-
bated for another 24 h, following which the cell viability was 
determined using ccK-8 (dojindo Molecular Technologies, 
Inc.). To determine cell viability, the HepG2 cells were seeded 
in 96-well plates at a density of 1x104 cells/ml and grown for 
24 h in a 37˚C incubator. When the cells attained 70‑80% 
confluence, they were either left untreated (control group) or 
treated with D‑GalN (50 mM), 5% hPH, or 5% hPH + D‑GalN 
(50 mM). Following incubation for 24 h, cell morphology 
changes were observed under Olympus inverted microscopes 
(Olympus corporation, Tokyo, Japan). The supernatants 
were discarded, following which 10% CCK‑8 solution in 
fresh dMEM (100 µl) were added to each well. The cells 
were then incubated at 37˚C for 1 h, and the absorbance was 
measured at 450 nm directly in the wells using a SpectraMax 
i3x Multi-Mode detection platform (Molecular devices LLc, 
Sunnyvale, cA, USA).
Measurement of LDH release. The LdH in the culture 
medium was assessed with 0.2 mM NAdH and 0.4 mM 
pyruvic acid in up to 200 µl PBS at pH 7.4. The LdH concen-
tration in the sample was proportional to the rate of NAdH 
oxidation measured by absorbance at 334 nm (Od/min) using 
the SpectraMax i3x Multi-Mode detection platform. The LdH 
concentration in the culture media was calculated using a 
commercial standard LdH assay kit purchased from Abnova 
(cat. no. KA0785, Taipei, Taiwan).
DAPI staining. Morphological changes in the apoptotic cells 
were assessed by fluorescent microscopy following dAPI 
staining. Briefly, the HepG2 cells were seeded at a density of 
1x105 cells/ml in 6‑well plates and grown for 24 h in a 37˚C 
incubator. Following washing once with PBS, the cells were 
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either left untreated (control group) or treated with d-GalN 
(50 mM), 5% hPH, or 5% hPH + D‑GalN (50 mM). Following 
incubation for 24 h, the cells were fixed in 4% formaldehyde 
for 1 h, and permeabilized with 0.1% Triton X‑100 (Biosesang, 
Inc., Seongnam, Korea) for 5 min. Subsequently, DNA‑specific 
fluorochrome dAPI (Invitrogen; Thermo Fisher Scientific, 
Inc.) was applied to each well, following which samples were 
incubated for 10 min in the dark at room temperature. Finally, 
the cells were washed three times with PBS and examined 
using a confocal microscope (carl Zeiss AG, Oberkochen, 
Germany).
Annexin V‑fluorescein isothiocyanate (FITC)/propidium 
iodide (PI) staining and fluorescence images. For apoptotic 
cell analysis, the HepG2 (1x104/well) cultures in 96-well black 
plates were exposed to the indicated treatments for 12 h. The 
assay was performed according to the manufacturer's protocol 
(Bd Biosciences, San Jose, cA, USA). Briefly, the cells 
were washed twice with PBS and again with binding buffer. 
Annexin V‑fluorescein isothiocyanate and PI were added to 
each sample, and the mixture was incubated at room tempera-
ture for 15 min. The absorbance was read directly in the wells 
at 494/518 nm for FITc Annexin V and 535/617 nm for PI 
using the SpectraMax i3x Multi-Mode detection platform. 
The populations staining positive for Annexin V and Pl were 
compared with the untreated group.
The HepG2 cells were grown to ~70% confluence; 
1x105 cells were collected in a Petri dish and either left 
untreated (control group) or treated with D‑GalN (50 mM), 5% 
hPH, or 5% hPH + D‑GalN (50 mM); and then incubated for 
24 h. The cells were then washed with PBS and stained with 
10 µg/ml PI for 5 min, and fluorescent images were observed 
under a DP70 fluorescence microscope with DP Controller 
software (Olympus corporation; ver. 3.2.276.2).
Measurement of ROS. cytosolic and mitochondrial ROS 
were measured on a 96-well plate reader as previously 
described (28). Briefly, the HepG2 cells were seeded at a 
concentration of 1x104 cells per well in black 96-well flat 
bottom plates (Thermo Fisher Scientific, Inc.) and allowed to 
adhere overnight. Following seeding, the cells were washed 
and incubated with serum-starved medium, d-GalN (50 nM), 
5% hPH, or 5% hPH + D‑GalN (50 mM) for 4 h, followed by 
incubation with 2',7'‑dichlorofluorescin diacetate (DCFH‑DA; 
10 µM, ex/em: 518/605 nm; Invitrogen; Thermo Fisher 
Scientific, Inc.) or MitoSOX™ (5 µM, ex/em: 510/580 nm; 
Invitrogen; Thermo Fisher Scientific, Inc.) for 20 min. The 
oxidative products were measured with the SpectraMax i3x 
Multi-Mode detection platform.
Measurement of mitochondrial membrane potential (ΔΨm). 
The ΔΨm of intact cells was measured as previously 
described, (29) with modifications. Briefly, the cells were 
washed with PBS and TMRE (200 nM, ex/em: 549/582 nm; 
Invitrogen; Thermo Fisher Scientific, Inc.) was added to the 
cell suspension. The cells were incubated at 37˚C for 30 min 
in the dark. The ΔΨm was measured using the SpectraMax 
i3x Multi-Mode detection platform. The percentage and mean 
fluorescence intensity level of the mass were calculated for 
each sample.
Determination of mitochondrial mass. Mitochondrial mass 
was measured according to fluorescence levels following 
staining with MitoTracker Green FM (100 nM, ex/em: 
490/525 nm; Invitrogen; Thermo Fisher Scientific, Inc.) at 37˚C 
for 30 min. Subsequently, the cells were washed once in PBS 
and promptly evaluated using the SpectraMax i3x Multi-Mode 
detection platform. The percentage and mean fluorescence 
intensity level of the mass were calculated for each sample.
Fluorescence microscopy. The cells (1x106 cells/well) were 
prepared on sterilized glass coverslips (Bd Biosciences) in 
triplicate and then fixed in 4% paraformaldehyde in PBS for 
10 min, permeabilized with 0.25% Triton X‑100 in PBS for 
10 min and incubated with primary antibodies against Tomm20 
(Abcam; 1:500), Nrf2 (Santa cruz Biotechnology, Inc.; 1:500), 
and LC3 (Abcam; 1:500) for 12 h at 4˚C incubator. The cells 
were washed to remove excess primary antibodies and incu-
bated with the appropriate fluorescently labeled secondary 
antibodies (1:1,000) for 1 h at room temperature. Following 
mounting of slides, fluorescence images were acquired using a 
confocal microscope (LSM700, carl Zeiss AG).
Western blot analysis. The cells were lysed in cell lysis buffer 
[62.5 mM Tris‑HCl (pH 6.8), 2% sodium dodecyl sulfate 
(SDS), 5% β-mercaptoethanol, 2 mM phenylmethylsulfonyl 
fluoride, protease inhibitors (Complete™; Roche Diagnostics 
GmbH, Mannheim, Germany), 1 mM Na3VO4, 50 mM NaF 
and 10 mM EdTA]. The protein content of the lysates was 
determined using BcA Protein Assay reagent (cat. no. 23225; 
Pierce; Thermo Fisher Scientific, Inc.). A 20 µg sample of 
protein per lane was separated by 12% SDS‑polyacrylamide 
gel electrophoresis and blotted onto polyvinylidene fluoride 
membranes (EMd Millipore) which were then saturated with 
5% powdered milk in Tris‑buffered saline containing 0.5% 
Tween-20. The blots were then incubated with the appropriate 
primary antibodies at a dilution of 1:1,000 or 1:2,000 for 12 h 
in a 4˚C incubator, and further incubated with horseradish 
peroxidase-conjugated secondary antibody (1:10,000) for 2 h 
at 37˚C. The bound antibodies were detected using enhanced 
chemiluminescence (Amersham; GE Healthcare Life 
Sciences, chalfont, UK). Images of the blotted membranes 
were captured using the LAS-1000 lumino-image analyzer 
(Fujifilm, Tokyo, Japan). The protein levels were compared 
to those of the appropriate loading control (GAPdH or 
non-phosphorylated proteins).
Reverse transcription‑quantitative polymerase chain reaction 
(RT‑qPCR) analysis. Total RNA was extracted from the dorsal 
skin using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.). 
First-strand cdNA synthesis from the total RNA template 
was performed with PrimeScript RT master mix (Takara 
Bio, Inc., Tokyo, Japan). The resulting cdNA was subjected 
to real-time PcR (complementary cdNA, 2 µl; primer, 3 µl; 
2X premix SYBR, 5 µl), using qPcR 2X PreMIX SYBR 
(Enzynomics, Seoul, Korea) and a cFX-96 thermocycler 
(Bio-Rad Laboratories, Inc., Hercules, cA, USA). The PcR 
conditions used to amplify all genes were as follows: 10 min 
at 95˚C and 40 cycles of 95˚C for 10 sec, 60˚C for 15 sec, and 
72˚C for 20 sec. The expression data were calculated from 
the quantification cycle (Cq) value using the ∆cq method of 
INTERNATIONAL JOURNAL OF MOLEcULAR MEdIcINE  42:  2569-2583,  2018 2573
quantification (30). GAPDH was used for normalization. The 
oligonucleotides that were used for qPcR were as follows: 
Human ATG8, forward 5'-cGc Acc TTc GAA cAA AGA 
GT-3' and reverse, 5'-GAc cAT GcT GTG Tcc GTT c-3'; 
human beclin 1 (BEcN1), forward 5'-AAc cTc AGc cGA 
AGA cTG AA-3' and reverse, 5'-ccT cTA GTG ccA GcT ccT 
TT-3'; human cathepsin d (cTSd), forward 5'-cAA GTT cGA 
TGG cAT ccT GG-3' and reverse 5'-cGG GTG AcA TTc AGG 
TAG GA-3'; human lysosomal-associated membrane protein 1 
(LAMP1), forward 5'-cTT TcA AGG TGG AAG GTGz Gc-3' 
and reverse 5'-GAT AGT cTG GTA Gcc TGc GT-3'; human 
activating transcription factor (ATF)6, forward 5'-GTG TcA 
GAG AAc cAG AGG cT-3' and reverse 5'-GGT Gcc Tcc TTT 
GAT TTG cA-3'; human ATF4, forward 5'-AcA cTG cTT AcG 
TTG ccA TG-3' and reverse 5'-AGA ccc AcA GAG AAc Acc 
TG-3'; human c/EBP homologous protein (cHOP), forward 
5'-cAT TGc cTT TcT ccT TcG GGG-3' and reverse 5'-ccA 
GAG AAG cAG GGT cAA GA-3'.
Statistical analysis. All quantitative data are presented as 
the mean ± standard error of the mean for three independent 
experiments. Statistical analyses were performed using the 
statistical package for SPSS software version 17.0 (IBM 
corp., Armonk, NY, USA). differences between two groups 
were evaluated using a paired Student's t-test. For multiple 
comparisons, one-way analysis of variance was used followed 
by Tukey's multiple comparisons test. P<0.05 was considered 
to indicate a statistically significant difference.
Results
Effects of hPH on mortality rates of D‑GalN/LPS‑treated rats. 
Acute liver injury leads to high mortality rates in rats. Therefore, 
the present study assessed the effects of hPH on d-GalN 
(700 mg/gg)/LPS (15 µg/kg)-induced mortality. To investigate 
whether hPH can protect against liver injury in rats due to 
d-GalN/LPS, the survival rate of d-GalN/LPS + hPH‑treated 
rats was monitored for 24 h (n=12). All saline-injected rats 
survived as the normal control group (n=12). No significant 
differences in gross liver examination, body weight, or liver 
weight were found between groups (Fig. 1A-c). As shown 
in Fig. 1d, a number of rats died 7 h following d-GalN/LPS 
injection, and the survival rate was 33.3% at 24 h. However, 
it was found that hPH pretreatment effectively increased the 
survival rate of rats with liver injury induced by d-GalN/LPS. 
Pretreatment with hPH (1.2 ml/kg) increased the survival rate 
to 83.3%, and all hPH (2.4 and 3.6 ml/kg)-treated rats survived. 
These results suggested that pretreatment with hPH effectively 
protected against d-GalN/LPS-induced mortality.
Effects of hPH on serum levels of ALT, AST, and inflamma‑
tory cytokines in LPS/GalN‑induced liver failure in rats. The 
serum levels of AST, ALT, LDH, and inflammatory cytokines 
are well-established markers of hepatic injury (31). In order to 
investigate the effects of hPH on d-GalN/LPS-induced liver 
damage, hematological tests were performed. Serum (n=4-6) 
was collected to detect AST, ALT, LdH, IL-6, and TNF-α. As 
shown in Fig. 1E-G, LPS/d-GalN markedly increased serum 
levels of AST, ALT, and LdH, whereas hPH reduced these 
elevations. As hepatocyte injury resulting from acute liver 
injury is accompanied by an elevation in inflammatory cyto-
kines (32), the present study examined the effect of hPH on 
hepatotoxicity by measuring serum levels of IL-6 and TNF-α 
(Fig. 1H and I). The d-GalN/LPS-treated rats exhibited signif-
icant increases in levels of IL-6 and TNF-α compared with 
normal rats. In addition, hPH pretreatment significantly inhib-
ited the release of these pro‑inflammatory cytokines compared 
with the LPS/d-GalN group. These results suggested that 
hPH effectively protected against LPS/d-GalN-induced liver 
degeneration and inflammatory responses.
Effects of hPH on hepatotoxicity of hepatocytes. The present 
study also investigated histological changes following liver 
injury to confirm the protective effects of hPH. The rats 
treated with d-GalN/LPS showed severe histopathological 
degeneration evidenced by severe intrahepatic hemorrhaging, 
apoptosis, necrosis, ballooned hepatocytes, and hepatocytes 
expanded by fat vacuoles, whereas hPH (1.2, 2.4 and 3.6 ml/kg) 
treatment ameliorated these changes (Fig. 2A). It has been 
suggested that d-galN/LPS-induced imbalance between 
apoptosis and proliferation in hepatocytes is responsible for 
the impairment of liver function. Therefore, hPH-mediated 
modulations of proliferation (PcNA) and apoptosis (TUNEL) 
were also evaluated by immunohistochemical analysis 
(Fig. 2B and c). A high expression of PcNA and low numbers 
of TUNEL-positive cells were observed in the control group. 
However, d-GalN/LPS markedly reduced PcNA immunore-
activity and significantly increased the number of apoptotic 
cells. By contrast, pre-administration of hPH resulted in an 
increase of PcNA-positive cells and reduced the number of 
apoptotic cells in all three dose groups. Graphs showing results 
of the staining experiments are shown in Fig. 2d-F. These 
observations indicated that hPH pretreatment ameliorated 
hepatic injury by reducing d-GalN/LPS-induced hepatocyte 
damage in rats.
hPH protects hepatocytes against D‑GalN‑induced apoptosis. 
Hepatocyte apoptosis is important in the pathogenesis of liver 
disease, including ALF (33). d-GalN induces hepatocyte 
cell death in vivo (34) and in vitro (35); it offers a suitable 
experimental model based on its capacity to reduce the intra-
cellular pool of uridine monophosphate in hepatocytes, 
inhibiting the synthesis of RNA and proteins, and leading 
to cell apoptosis. Therefore, the present study investigated 
whether d-GalN-induced hepatotoxicity occurred in HepG2 
cells. Following d-GalN stimulation, cell viability decreased 
markedly in a dose-dependent manner. The results revealed a 
reduction of 50% at 50 mM D‑GalN and of 82% at 100 mM 
d-GalN in the HepG2 cells (Fig. 3A). The cytotoxic effects 
of hPH on HepG2 cells have not been examined previ-
ously. The present study used a ccK-8 assay to evaluate the 
dose-dependent cytotoxic effects of hPH on HepG2 cells. The 
results showed that stimulation with hPH had no significant 
effect on cell viability at various concentrations (1.25‑5% in 
serum-free dMEM) over 24 h. Therefore, hPH was used at 
a concentration of 5% in subsequent experiments (Fig. 3B). 
In addition to the d-GalN-induced decrease in cell viability 
being attenuated by pretreatment with hPH, the concentration 
of LdH released from the hepatocytes was also reduced in 
the D‑GalN + 5% hPH‑stimulated cells, compared with the 
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d-GalN only-treated cells (Fig. 3c and d). These results 
indicated that hPH protected against d-GalN-induced hepato-
toxicity in HepG2 cells. changes in cellular morphology and 
cell viability were also evaluated to examine the protective 
effects of hPH in d-GalN-stimulated HepG2 cells. As shown 
in Fig. 3E, the d-GalN-stimulated HepG2 cells exhibited a 
marked reduction in the number of hepatocytes. However, hPH 
pretreatment effectively improved the d-GalN-mediated cell 
damages.
To examine the inhibitory mechanisms of hPH in 
d-GalN-induced cytotoxicity, the HepG2 cells were assessed 
by Annexin V and PI staining, followed by microplate analysis 
(Fig. 3F and G) or fluorescence microscopy (Fig. 3H). D‑GalN 
stimulation alone facilitated the induction of apoptosis, including 
levels of Annexin V+ (841%)/PI+ (948%), compared with the 
controls. By contrast, pretreatment with hPH significantly inhib-
ited d-GalN-induced apoptosis (Annexin V+, 801%; PI+, 280%). 
d-GalN-induced dNA fragmentation was also effectively 
attenuated by hPH pretreatment (Fig. 3H). The present study 
further examined whether hPH regulated PARP-dependent 
cell death. d-GalN induced an increase of Bax (pro-apoptotic 
protein) and a decrease of Bcl-2 (anti-apoptotic protein) (Fig. 3I 
and J). Furthermore, the cleavage of PARP was inhibited in the 
HepG2 cells by pretreatment with hPH (Fig. 3I and J). These 
findings suggested that hPH treatment significantly improved 
hepatocyte degeneration through the attenuation of apoptosis in 
HepG2 cells.
hPH regulates D‑GalN‑mediated intracellular ROS genera‑
tion and mitochondrial dysfunction. The rapid generation of 
Figure 1. Protective effects of hPH treatment on d-GalN/LPS-induced acute liver failure. hPH (1.2, 2.4, or 3.6 ml/kg) was subcutaneously administered to 
rats three times at intervals of 24 h, followed by exposure to 700 mg/kg d-GalN and 15 µg/kg LPS (d-GalN/LPS). Livers from each experimental group were 
examined 24 h following D‑GalN/LPS challenge. (A) Gross image of livers. Scale bar=1 cm (B) Animal weights (n=4‑6) were measured just prior to sacrifice; 
with no statistical difference among groups. (C) Liver weights were measured following sacrifice, with no statistical difference among groups (n=4‑6). 
(d) Survival rates of rats were observed for 24 h following d-GalN/LPS exposure (n=12). Serum (n=4-6) was collected from animals 24 h following exposure 
to d-GalN/LPS to determine levels of (E) AST, (F) ALT, (G) LdH, (H) IL-6, and (I) TNF-α. All data are presented as the mean ± standard error of the mean. 
*P<0.05 and **P<0.01, vs. d-GalN/LPS group. hPH, human placental hydrolysate; d-GalN, d-galactosamine; LPS, lipopolysaccharide; cont, control; AST, 
aspartate aminotransferase; ALT, alanine aminotransferase; LdH, lactate dehydrogenase; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α.
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ROS is associated with hyperpolarization of the mitochondrial 
membrane potential and apoptosis in d-GalN-treated hepa-
tocytes (36). In addition, d-GalN-dependent cell necrosis is 
associated with mitochondrial membrane depolarization (37). 
To investigate whether the d-GalN-mediated increase in 
abnormal mitochondria was rescued by hPH treatment, the 
present study first evaluated mitochondrial morphology 
using Tomm20 (mitochondrial outer membrane) staining 
(Fig. 4A). Mitochondrial morphology was altered at 24 h in 
the d-GalN-stimulated HepG2 cells. However, the increased 
mitochondrial damage was attenuated significantly by hPH. 
In addition, mitochondrial mass decreased, by ~55%, in the 
d-GalN-stimulated HepG2 cells, and this was rescued by 
hPH pretreatment (Fig. 4B). ΔΨm was then evaluated using 
microplate analysis. The d-GalN-stimulated HepG2 cells 
exhibited decreased ΔΨm; however, this decrease was signifi-
cantly attenuated in the hPH-pretreated cells and unstimulated 
cells (Fig. 4C). These findings suggested that hPH improved 
d-GalN-mediated mitochondrial dysfunction by improving 
ΔΨm and inhibiting quantitative mitochondria loss. 
Subsequently, the present study determined whether hPH 
was involved in the negative regulation of oxidative stress. 
The HepG2 cells were stimulated with d-GalN in the pres-
ence or absence of hPH, and ROS generation was determined 
using dcFH-dA or MitoSOX (mitochondrial-specific 
superoxide indicator) (38) as a probe for microplate analyses 
(Fig. 4d and E). d-GalN alone led to the potent intracellular 
generation of ROS, whereas the d-GalN-induced genera-
tion of ROS in HepG2 cells was attenuated significantly by 
hPH pretreatment (Fig. 4d). Mitochondrial ROS increased 
Figure 2. Effects of hPH treatment on d-GalN/LPS-induced acute liver failure in tissue degeneration and apoptosis. (A) Histopathological staining. Upper 
panel (magnification, x20), lower panel (magnification, x40). Scale bar=100 µm. The arrows indicate apoptotic hepatocytes (black), a severely affected region 
of a lobule containing ballooned hepatocytes (red), and hepatocytes expanded by fat vacuoles (green). (B) Images showing PcNA staining. Scale bar=100 µm. 
(c) Apoptotic response to d-GalN/LPS in the liver tissue of rats was investigated using TUNEL staining. Scale bar=100 µm. (d) Stained sections were graded 
for histopathology using a four-point scale (0-3), with 0, 1, 2, and 3 representing no damage, mild damage, moderate damage, and severe damage, respectively. 
(E) PCNA‑positive cells were significantly less numerous in the D‑GalN/LPS‑treated group than in the control group; the addition of hPH led to significant 
overexpression of PcNA in the liver compared with d-GalN/LPS treatment alone. (F) TUNEL-positive cells was higher in number in the group treated with 
d-GalN/LPS alone compared with the control group. However, apoptotic induction by d-GalN/LPS was further reduced in the groups treated with 1.2, 2.4, 
and 3.6 ml/kg of hPH. All data are presented as the mean ± standard error of the mean. *P<0.05 and **P<0.01, vs. d-GalN/LPS group. hPH, human placental 
hydrolysate; d-GalN, d-galactosamine; LPS, lipopolysaccharide; PcNA, proliferating cell nuclear antigen; cont, control.
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significantly following treatment with d-GalN (Fig. 4E), 
whereas d-GalN-induced mitochondrial ROS generation 
was decreased by pretreatment with hPH. These results 
suggested that hPH protected against d-GalN-mediated 
Figure 3. Effects of hPH treatment on d-GalN-induced apoptosis in HepG2 cells. (A) HepG2 cells were treated with 25, 50, or 100 mM d-GalN for 24 h. 
Treatment with 50 mM D‑GalN yielded a cell viability of almost 50% compared with the vehicle control. The concentration of 50 mM D‑GalN was used to 
determine the 50% inhibitory concentration. (B) HepG2 cells were treated with increasing concentrations of hPH or vehicle control for 24 h. HepG2 cells were 
treated with hPH (5%) for 2 h prior to D‑GalN stimulation (50 mM). After 24 h, the hepatoprotective effects of hPH were assessed with the (C) Cell Counting 
Kit-8 assay and (d) LdH release test for cell viability, and with an (E) inverted phase-contrast microscope for morphological changes (scale bar=50 µm). 
HepG2 cells were stimulated with D‑GalN (50 mM, 24 h) in the presence or absence of 5% hPH. (F) Cells were subjected to fluorescence microscopy (PI stain 
only) and (G) Annexin V/PI staining analyzed by a microplate (scale bar=50 µm). (H) dNA fragmentation (red arrow) and nuclear condensation (white 
arrow) were detected by dAPI staining under each condition (scale bar=5 µm). For western blot analysis, cell lysates were collected and subjected to sodium 
dodecyl sulfate-PAGE, followed by immunoblot analysis using anti-BcL2, anti-BAX and anti-PARP antibodies. Anti-GAPdH was used as a loading control. 
(I) Representative images and (J) densitometry. All data are presented as the mean ± standard error of the mean. **P<0.01, vs. d-GalN group. hPH, human 
placental hydrolysate; d-GalN, d-galactosamine; cont, control; LdH, lactate dehydrogenase; BcL2, B-cell lymphoma 2; BAX, Bcl-2-associated X protein; 
PARP, poly (AdP) ribose polymerase; PI, propidium iodide.
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apoptotic cell death by regulating the generation of cytosolic 
and mitochondrial ROS.
hPH regulates expression of antioxidant enzymes in HepG2 
cells. As the induction of antioxidant enzymes is a universal 
stress response against liver degeneration and has been widely 
shown to have an anti-apoptotic effect, the expression levels 
of antioxidative enzymes SOd1, SOd2, GPx, and catalase 
were detected by western blot analysis (Fig. 5A). hPH induced 
antioxidative enzyme expression in the HepG2 cells. These 
enzymes were elevated 1 h following hPH treatment and were 
maintained at this level until 8 h. Furthermore, to investigate 
the antioxidant mechanisms of hPH, Nrf2 pathway-related 
gene expression on HepG2 cells was evaluated (Fig. 5B-d). The 
induction of Nrf2 upregulates antioxidant proteins, including 
SOd, catalase, and HO-1, reducing ROS (15). hPH treatment 
resulted in a significant decrease of Keap1 at 4‑8 h. However, 
hPH increased the protein levels of cytoplasmic p-p62 and 
HO-1. Additionally, p62 was upregulated 4-8 h following hpH 
treatment (Fig. 5B). Furthermore, the expression of Nrf2 was 
decreased in the cytosol and increased in the nucleus (active 
Nrf2) following hPH treatment, indicating that translocation 
to the nucleus was affected by hPH treatment (Fig. 5c and d). 
Together, these findings indicated that the induction of anti-
oxidative enzymes by hPH treatment was modulated by the 
Keap1-p62-Nrf2 pathway.
hPH minimizes the expression of damage‑related molecules 
via the regulation of autophagy. Autophagy, mitochon-
dria, and oxidative stress are closely intertwined in redox 
signalling (39). Additionally, d-GalN-induced cell damage 
regulates the autophagy process in early stages. To inves-
tigate whether the regulation of autophagy is influenced 
by d-GalN stimulation and the effects of hPH, the present 
study measured the level of autophagy regulation by staining 
cells with anti-Lc3 I/II antibody (Fig. 6A). Lc3 I/II is an 
established autophagy marker due to its involvement in 
autophagosome membrane formation (40). In the present 
study, compared with the cells treated with vehicle control or 
D‑GalN alone, the cells treated with hPH exhibited signifi-
cantly fewer Lc3 puncta per cell (Fig. 6A). The changes in 
autophagy‑related genes were then quantified through assess-
ment of RNA and protein levels in the hPH-treated HepG2 
cells. As shown in Fig. 6B and c, hPH treatment induced 
a decrease in the conversion of Lc3-I to Lc3-II (lipidated 
form), the latter of which is a reliable marker of autopha-
gosome generation. Furthermore, the expression levels of 
dRAM, cHOP, and p53 (proteins associated with autophagic 
cell death) indicated that a minimized autophagy process 
was induced in the hPH-treated cells (Fig. 6B) (20,41,42). 
Similarly, the transcription levels of autophagy-related 
genes (ATG8, cTSd, BEcN1, and LAMP1) and of ER 
stress-related genes (ATF4, ATF6, and cHOP) were lower 
in the hPH-treated cells compared with those in cells treated 
with d-GalN only (Fig. 6c). These results suggested that 
hPH treatment minimized the escalation of d-GalN-induced 
autophagy processes in HepG2 cells.
Discussion
Apoptosis and oxidative stress are interrelated biological 
events that are involved in the pathogenesis of various 
diseases, including ALF (43-46). Emerging evidence 
suggests that d-GalN/LPS-induced oxidative stress gives 
rise to hepatic injuries resulting from oxidative stress and 
apoptosis, which parallel those of liver degeneration (6,7). 
Figure 4. d-GalN-induced mitochondrial dysfunction and ROS overgeneration in HepG2 cells are improved by hPH treatment. HepG2 cells were stimulated 
with D‑GalN (50 mM, 24 h) in the presence or absence of 5% hPH. (A) HepG2 cells post‑hPH treatment were immunostained with anti‑Tomm20 antibody, 
followed by the addition of Cy3‑conjugated secondary antibody. Nuclei were identified using DAPI staining (scale bar=5 µm). (B) MitoTracker fluorescence 
signals for mitochondrial mass were measured. (c) ΔΨm was measured under the indicated conditions using the ΔΨm‑sensitive fluorochrome MitoTracker 
Red CMXRos. (D) Cells were stained with 2',7'‑dichlorofluorescin diacetate for 30 min to measure intracellular hydrogen peroxide. (E) Cells were stained 
with MitoSOX for 30 min to measure mitochondrial ROS. Bar graphs show relative analysis. All data are presented as the mean ± standard error of the mean. 
**P<0.01, vs. d-GalN group. hPH, human placental hydrolysate; d-GalN, d-galactosamine; con, control; MMP/ΔΨm, mitochondrial membrane potential; 
ROS, reactive oxygen species.
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In addition, d-GalN/LPS-induced ALF is widely accepted 
as an experimental liver injury animal model, contributing 
to investigation of the mechanisms underlying clinical liver 
injury and the development of efficient hepatoprotective 
materials (47-51). Accordingly, any approach that relieves 
apoptosis and oxidative stress in vitro and in vivo contributes 
to the prevention or treatment of ALF. In the present study, 
it was demonstrated that pretreatment with hPH attenuated 
acute liver injury associated with elevated serum levels of 
ALP, AST, LdH, and pro-inflammatory cytokines (IL-6 
and TNF-α). Furthermore, it was found that apoptosis 
was increased following d-GalN/LPS injection, whereas 
pretreatment with hPH effectively inhibited tissue degen-
eration and increased cell death in d-GalN/LPS-induced 
acute liver injury. Pretreatment with hPH also reversed the 
extensive vacuolization, severe intrahepatic hemorrhage, 
destruction of nuclei, and loss of hepatic cords. consistently, 
it has been reported that hPH possesses a variety of biolog-
ical activities, including anti‑inflammatory (26,52‑56) and 
antioxidant (26,57-59) properties. Exposure to hazardous 
components from the environment can lead to pregnancy 
loss, uterine dysfunction, or fetal death (60). It has been 
reported that oxidative stress is mainly or partly involved in 
damage from these harmful environments (61). Therefore, 
the human placenta contains antioxidant defense substances 
to protect embryos from oxidative stress (62-64). Human 
placenta extract prepared from the placenta of healthy preg-
nant females is known to have various physiological actions, 
including antioxidative properties (57,65). In the present study, 
hPH was prepared with human placenta, including umbilical 
cord, following the provision of consent from the pregnant 
women. The hydrolysate of human placenta is manufactured 
by a chemical process with Hcl and pepsin, followed by 
dialysis, heat treatment and hydrolysis. This hydrolysate 
contains various amino acids, including arginine (0.08%), 
lysine (0.1%), phenylalanine (0.08%), tyrosine (0.03%), 
leucine (0.12%), methionine (0.03%), valine (0.04%), alanine 
(0.08%), serine (0.07%), and threonine (0.06%). Based on 
this, hPH is considered to contain the cleaved proteins of the 
amino acids and their active ingredients.
In previous studies, it has been reported that d-GalN 
leads to cytotoxicity and apoptotic cell death in HepG2 
cells (66-68). d-GalN/LPS intoxication causes an imbal-
ance between pro-oxidants and antioxidants, involving the 
excessive production of ROS and a deficiency of cellular anti-
oxidants, including glutathione, catalase and SOd. Oxidative 
stress caused by d-GalN/LPS is a recognized phenomenon 
in liver damage (47,69-71). In addition, d-GalN/LPS induces 
loss of ΔΨm and production of ROS, resulting in liver 
damage (36,72-74). Mitochondria are the major subcellular 
organelles responsible for ROS production (75). The results 
of the present study demonstrated that hPH enhanced the 
expression of SOd-1, SOd-2, catalase and GPx, and increased 
the nuclear translocation of the Nrf2 via a Keap1-p62-Nrf2 
mechanism. The upregulation of various important anti-
oxidants is caused by the binding of Nrf2 to the ARE of 
Figure 5. Upregulation of antioxidant enzymes and regulation of Keap1-Nrf2 in hPH-treated HepG2 cells. (A) Lysates from hPH-induced HepG2 cells were 
immunoblotted with anti-SOd-1, anti-SOd-2, anti-GPx, or anti-catalase antibodies. Representative images (left penal), densitometry results (right panel). All 
data are presented as the mean ± standard error of the mean. *P<0.05, **P<0.01 vs. 0 h time point. (B) Following treatment with hPH, the expression levels 
of p-p62, p62, Keap1, and HO-1 were determined by western blot analysis. Representative images (left penal), densitometry results (right panel). All data 
are presented as the mean ± standard error of the mean. *P<0.05, **P<0.01, vs. 0 h time point. (c) Nuclear localization of Nrf2 in hPH-treated HepG2 cells 
compared with untreated HepG2 cells. Lysates from hPH-treated HepG2 cells were immunoblotted with anti-Nrf2, anti-Lamin B1, or anti-GAPdH antibodies. 
Representative images (left penal), densitometry results (right panel). All data are presented as the mean ± standard error of the mean. *P<0.05, **P<0.01, vs. 0 h 
time point. (D) HepG2 cells post‑hPH treatment were immunostained with anti‑Nrf2 antibody. Nuclei were identified using DAPI staining (scale bar=20 µm). 
hPH, human placental hydrolysate; SOd, superoxide dismutase; GPx, glutathione peroxidase; Keap1, Kelch-like EcH2-associated protein 1; HO-1, heme 
oxygenase-1; p-p62; Nrf2, nuclear factor-E2-related factor 2. 
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antioxidant target proteins, including SOd, catalase, NQO1, 
GcLM and HO-1 (15,16). Nrf2 has been regarded as a novel 
therapeutic target for the treatment of liver disease (76-80). 
In Nrf2-deficient mice, the expression of various cytopro-
tective enzymes was decreased in hepatocytes, resulting in 
oxidative stress and markedly delayed liver regeneration (81). 
In addition, genetic disruption of Nrf2 triggers the progres-
sion of necroinflammation and hepatic fibrosis in Hfe-/- mice 
presenting with no liver injury (82). Pretreatment with 
sulforaphane prevents hepatic damage induced by intestinal 
ischemia/reperfusion in rats through an antioxidative effect 
via the Nrf2-ARE pathway (79). Another study showed that 
the expression of Nrf2 was upregulated to protect the liver 
from inflammatory damage caused by oxidative stress during 
the development of non-alcoholic fatty liver and steatohepa-
titis (78). Additionally, Farombi et al reported that curcumin 
(diferuloymethane) administration promoted the nuclear 
translocation and ARE-binding of Nrf2, leading to preven-
tion of dimethylnitrosamine-induced hepatotoxicity (76). In 
addition, β-cryptoxanthin was found to ameliorate visceral 
fat and cardiometabolic health risk factors by modulating the 
expression of nuclear factor-κB and Nrf2 in rats fed a high-fat 
diet (83). 
Autophagy is an evolutionarily conserved homeostatic 
process and lysosome-dependent proteolytic pathway, which 
is involved in a variety of physiological and pathological 
Figure 6. hPH treatment results in altered autophagy regulation in HepG2 cells following d-GalN stimulation. (A) HepG2 cells treated with hPH exhibit 
minimized autophagy flux. To detect autophagosomes, cells were immunostained with anti‑LC3 antibody. Nuclei were identified using DAPI staining (scale 
bar=10 µm). (B) cell lysates were immunoblotted with anti-Lc3 I/II, anti-dRAM, anti-cHOP, anti-p53, or anti-GAPdH antibodies. Representative western 
blot images (left panel) and densitometry results (right panel). All data are presented as the mean ± standard error of the mean. **P<0.01, vs. d-GalN group. 
(c) Transcript levels of ER stress- and autophagy-related genes were determined by reverse transcription-quantitative polymerase chain reaction analysis. All 
data are presented as the mean ± standard error of the mean. **P<0.01, vs. d-GalN group. hPH, human placental hydrolysate; d-GalN, d-galactosamine; cont, 
control; Lc3, microtubule-associated protein 1A/1B-light chain 3; dRAM, damage-regulated autophagy modulator; cHOP, c/EBP homologous protein; ATF, 
activating transcription factor; BEcN1; beclin 1; LAMP1, lysosomal-associated membrane protein 1.
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processes (84,85). According to previous data, autophagy 
is involved in major liver diseases, including liver isch-
emia/reperfusion injury, hepatitis B and c, hepatocellular 
carcinoma, alcoholic liver disease and non-alcoholic fatty 
liver disease (86). In addition, autophagy is induced to main-
tain healthy cells in the presence of TNF-, acetaminophen-, 
or ethanol-induced liver injury (87-89). However, excessive 
autophagy can cause autophagic cell death. Previously, 
autophagy has been shown to be elevated in concanavalin 
A-induced acute hepatitis, leading to the autophagic 
cell death of hepatoma cells in ScId/NOd mice (90). 
Furthermore, autophagy inhibition significantly improved 
liver graft dysfunction and the survival rate of recipient rats 
with ‘cold ischemia-warm reperfusion injury’ associated 
with liver transplantation (91), suggesting that autophagy can 
aggravate liver damage. In the present study, it was found 
that excessive autophagy was induced following d-GalN 
administration, and that pretreatment with hPH effectively 
suppressed this enhanced autophagy in d-GalN-induced 
HepG2 cells. It also indicated a regulatory pathway mecha-
nism of autophagy induction and inhibition by d-GalN/hPH 
via the p53‑DRAM‑autophagy axis. The identification of 
dRAM as a p53 target mediating the induction of autophagy 
allowed for investigation of the role of autophagy in apop-
tosis (42). Liu et al reported that p53-induced apoptosis 
is primarily dependent on dRAM- and BAX-mediated 
autophagy in hepatosteatosis in oleic acid-treated HepG2 
cells and high-fat diet mice (92). The induction of autophagy 
by the nuclear translocation of p53 involves the upregula-
tion of dRAM and sestrin2 in p53-sufficient, but not in 
p53‑deficient cells (93). The expression of CHOP is regulated 
transcriptionally and post-transcriptionally in hPH-induced 
HepG2 cells. cHOP, a multifunctional transcription factor 
in the ER stress response, promotes autophagic apoptosis 
induced by various stimuli, including tetrahydrocannabinol, 
2-deoxy-d-glucose, rabbit hemorrhagic disease virus, and 
apoptosis-stimulating protein of p53-2 (94-97). The data 
obtained in the present study also demonstrated that hPH 
led to downregulation of the ER stress-related downstream 
targets, ATF4 and ATF6, in d-GalN-treated HepG2 cells. 
Based on the above findings, it was concluded that autophagy, 
apoptosis and ER stress are closely associated with each 
other, supported by the results of the present study. d-GalN 
stimulation increased the expression levels of dRAM, 
cHOP and the apoptosis-related protein p53 in HepG2 cells, 
whereas hPH pretreatment reversed the expression of these 
proteins. hPH pretreatment also resulted in Lc3 lipidation, 
but meaningfully minimized autophagosome expression 
compared with d-GalN alone.
In previous animal studies, early onset autophagy has been 
shown to increase liver injury, however, this observation has 
not been corroborated in patient populations. Therefore, the 
epidemiological relevance of autophagy and liver damage 
require investigation in the future. Taken together, the results 
of the present study showed that hPH had a protective effect 
on hepatocyte apoptosis through antioxidative modula-
tion and minimization of the autophagy process, which 
resulted in the inhibition of hepatocytotoxicity. This may be 
useful as a target for the treatment of acute liver injury. The 
identification of this pathway can assist in understanding 
the molecular events leading to the activation of oxidative 
stress- and autophagy-mediated cell death in human disease, 
and contribute to the design of novel therapeutic strategies 





This study was supported by Green cross WellBeing 
corporation, Korea (grant no. 20161015) and by the chung-Ang 
University Research Scholarship Grants in 2017.
Availability of data and materials
The analyzed data sets generated during the study are avail-
able from the corresponding author on reasonable request.
Authors' contributions
BJK, THK, dHB, JN, and MJc designed experiments; dHB, 
JN, and MJc performed experiments; MJK, BcL, THK, dHB, 
JN, MJc, cTO, JYK, and HJH analyzed data; cTO, JYK, and 
HJH prepared materials; DHB, JN, and MJC prepared figures; 
BJK, THK, dHB, and JN wrote the manuscript. BJK and 
THK had primary responsibility for final content. All authors 
have read and approved the final manuscript.
Ethics approval and consent to participate
The present study was approved by the Institutional 
Animal care and Use committee of chung-Ang University 
(2017-00003). Placental tissues were used following the provi-
sion of informed consent from the pregnant women.
Patient consent for publication
Not applicable.
Competing interests 
The authors declare that they have no competing interests.
References
 1. Bernal W, Auzinger G, dhawan A and Wendon J: Acute liver 
failure. Lancet 376: 190-201, 2010.
 2. Han dW: Intestinal endotoxemia as a pathogenetic mechanism in 
liver failure. World J Gastroenterol 8: 961-965, 2002.
 3. Sathivel A, Balavinayagamani, Hanumantha Rao BR and 
devaki T: Sulfated polysaccharide isolated from Ulva lactuca 
attenuates d-galactosamine induced dNA fragmentation and 
necrosis during liver damage in rats. Pharm Biol 52: 498-505, 
2014.
 4. Masaki T, chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M 
and Yoshimatsu H: Adiponectin protects LPS-induced liver 
injury through modulation of TNF-α in KK-Ay obese mice. 
Hepatology 40: 177-184, 2004.
 5. Wu Z, Han M, chen T, Yan W and Ning Q: Acute liver failure: 
Mechanisms of immune-mediated liver injury. Liver Int 30: 
782-794, 2010.
INTERNATIONAL JOURNAL OF MOLEcULAR MEdIcINE  42:  2569-2583,  2018 2581
 6. Sheriff SA, Shaik Ibrahim S, devaki T, chakraborty S, Agarwal S 
and Pérez-Sánchez H: Lycopene prevents mitochondrial 
dysfunction during d-galactosamine/lipopolysaccharide-induced 
fulminant hepatic failure in albino rats. J Proteome Res 16: 
3190-3199, 2017.
 7. dong L, Yin L, Quan H, chu Y and Lu J: Hepatoprotective 
effects of kaempferol-3-O-α-l-arabinopyranosyl-7-O-α-l-rhamn
opyranoside on d-Galactosamine and lipopolysaccharide caused 
hepatic failure in mice. Molecules 22: E1755, 2017.
 8. Lee SB, Kang JW, Kim SJ, Ahn J, Kim J and Lee SM: Afzelin 
ameliorates d-galactosamine and lipopolysaccharide-induced 
fulminant hepatic failure by modulating mitochondrial quality 
control and dynamics. Br J Pharmacol 174: 195-209, 2017.
 9. decker cW, casian JG, Nguyen KT, Horton LA, Rao MP, 
Silkwood KH and Han d: The critical role of mitochondria in 
drug-induced liver injury. In: Molecules, Systems and Signaling 
in Liver Injury. Springer, pp159-181, 2017.
10. Nguyen T, Nioi P and Pickett cB: The Nrf2-antioxidant response 
element signaling pathway and its activation by oxidative stress. 
J Biol chem 284: 13291-13295, 2009.
11. Bryan HK, Olayanju A, Goldring cE and Park BK: The Nrf2 
cell defence pathway: Keap1-dependent and-independent mecha-
nisms of regulation. Biochem Pharmacol 85: 705-717, 2013.
12. Zhou R, Lin J and Wu d: Sulforaphane induces Nrf2 and 
protects against cYP2E1-dependent binge alcohol-induced liver 
steatosis. Biochim Biophys Acta 1840: 209-218, 2014.
13. Jiang T, Huang Z, Lin Y, Zhang Z, Fang d and Zhang dd: 
The protective role of Nrf2 in streptozotocin-induced diabetic 
nephropathy. diabetes 59: 850-860, 2010.
14. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, chiba T, 
Igarashi K and Yamamoto M: Oxidative stress sensor Keap1 func-
tions as an adaptor for cul3-based E3 ligase to regulate proteasomal 
degradation of Nrf2. Mol cell Biol 24: 7130-7139, 2004.
15. Bataille A and Manautou J: Nrf2: A potential target for new 
therapeutics in liver disease. clin Pharmacol Ther 92: 340-348, 
2012.
16. Jian Z, Li K, Song P, Zhu G, Zhu L, cui T, Liu B, Tang L, 
Wang X, Wang G, et al: Impaired activation of the Nrf2-ARE 
signaling pathway undermines H2O2-induced oxidative stress 
response: A possible mechanism for melanocyte degeneration in 
vitiligo. J Invest dermatol 134: 2221-2230, 2014.
17. Mizushima N, Levine B, cuervo AM and Klionsky dJ: 
Autophagy fights disease through cellular self-digestion. 
Nature 451: 1069-1075, 2008.
18. Mizushima N and Komatsu M: Autophagy: Renovation of cells 
and tissues. cell 147: 728-741, 2011.
19. Gozuacik d and Kimchi A: Autophagy and cell death. curr Top 
dev Biol 78: 217-245, 2007.
20. crighton d, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, 
Gasco M, Garrone O, crook T and Ryan KM: dRAM, a 
p53-induced modulator of autophagy, is critical for apoptosis. 
cell 126: 121-134, 2006.
21. Tonello G, daglio M, Zaccarelli N, Sottofattori E, Mazzei M and 
Balbi A: characterization and quantitation of the active poly-
nucleotide fraction (PdRN) from human placenta, a tissue repair 
stimulating agent. J Pharm Biomed Anal 14: 1555-1560, 1996.
22. Sur TK, Biswas TK, Ali L and Mukherjee B: Anti‑inflammatory 
and anti-platelet aggregation activity of human placental extract. 
Acta Pharmacol Sin 24: 187-192, 2003.
23. Chakraborty PD and Bhattacharyya D: Isolation of fibronectin 
type III like peptide from human placental extract used as wound 
healer. J chromatogr B Analyt Technol Biomed Life Sci 818: 
67-73, 2005.
24. choi JY, Lee K, Lee SM, Yoo SH, Hwang SG, choi JY, Lee SW, 
Hwang JS, Kim KK, Kang Hc, et al: Efficacy and safety of 
human placental extract for alcoholic and nonalcoholic steato-
hepatitis: An open-label, randomized, comparative study. Biol 
Pharm Bull 37: 1853-1859, 2014.
25. Shimokobe H, Sumida Y, Tanaka S, Mori K, Kitamura Y, 
Fukumoto K, Kakutani A, Ohno T, Kanemasa K, Imai S, et al: 
Human placental extract treatment for non-alcoholic steato-
hepatitis non-responsive to lifestyle intervention: A pilot study. 
Hepatol Res 45: 1034-1040, 2015.
26. Park S, Phark S, Lee M, Lim J and Sul d: Anti-oxidative and 
anti‑inflammatory activities of placental extracts in benzo[a]
pyrene-exposed rats. Placenta 31: 873-879, 2010.
27. camargo cA Jr, Madden JF, Gao W, Selvan RS and clavien P: 
Interleukin-6 protects liver against warm ischemia/reperfusion 
injury and promotes hepatocyte proliferation in the rodent. 
Hepatology 26: 1513-1520, 1997.
28. Okoh VO, Felty Q, Parkash J, Poppiti R and Roy d: 
Reactive oxygen species via redox signaling to PI3K/AKT 
pathway contribute to the malignant growth of 4-hydroxy 
estradiol-transformed mammary epithelial cells. PLoS One 8: 
e54206, 2013.
29. Jasek E, Lis GJ, Jasińska M, Jurkowska H and Litwin JA: Effect 
of histone deacetylase inhibitors trichostatin A and valproic acid 
on etoposide-induced apoptosis in leukemia cells. Anticancer 
Res 32: 2791-2799, 2012.
30. Livak KJ and Schmittgen Td: Analysis of relative gene expres-
sion data using real-time quantitative PcR and the 2(-delta delta 
c(T)) method. Methods 25: 402-408, 2001.
31. cassidy W and Reynolds T: Serum lactic dehydrogenase in 
the differential diagnosis of acute hepatocellular injury. J clin 
Gastroenterol 19: 118-121, 1994.
32. Rolando N, Wade J, davalos M, Wendon J, Philpott-Howard J 
and Williams R: The systemic inflammatory response syndrome 
in acute liver failure. Hepatology 32: 734-739, 2000.
33. Guicciardi M and Gores GJ: Apoptosis: A mechanism of acute 
and chronic liver injury. Gut 54: 1024-1033, 2005.
34. Stachlewitz RF, Seabra V, Bradford B, Bradham cA, Rusyn I, 
Germolec d and Thurman RG: Glycine and uridine prevent 
d-galactosamine hepatotoxicity in the rat: Role of kupffer cells. 
Hepatology 29: 737-745, 1999.
35. Thabrew MI, Hughes Rd and McFarlane IG: Screening of hepa-
toprotective plant components using a HepG2 cell cytotoxicity 
assay. J Pharm Pharmacol 49: 1132-1135, 1997.
36. González R, Ferrín G, Hidalgo AB, Ranchal I, López-cillero P, 
Santos-Gónzalez M, López-Lluch G, Briceño J, Gómez MA, 
Poyato A, et al: N-acetylcysteine, coenzyme Q10 and superoxide 
dismutase mimetic prevent mitochondrial cell dysfunction and 
cell death induced by d-galactosamine in primary culture of 
human hepatocytes. chem Biol Interact 181: 95-106, 2009.
37. Zhao Y, Li S, childs EE, Kuharsky dK and Yin XM: Activation 
of pro-death Bcl-2 family proteins and mitochondria apoptosis 
pathway in tumor necrosis factor-α-induced liver injury. J Biol 
chem 276: 27432-27440, 2001.
38. Kuznetsov AV, Kehrer I, Kozlov AV, Haller M, Redl H, 
Hermann M, Grimm M and Troppmair J: Mitochondrial ROS 
production under cellular stress: comparison of different detec-
tion methods. Anal Bioanal chem 400: 2383-2390, 2011.
39. Lee J, Giordano S and Zhang J: Autophagy, mitochondria and 
oxidative stress: cross-talk and redox signalling. Biochem J 441: 
523-540, 2012.
40. Yang Z and Klionsky dJ: Mammalian autophagy: core molec-
ular machinery and signaling regulation. curr Opin cell Biol 22: 
124-131, 2010.
41. Liu GY, Jiang XX, Zhu X, He WY, Kuang YL, Ren K, Lin Y 
and Gou X: ROS activates JNK-mediated autophagy to coun-
teract apoptosis in mouse mesenchymal stem cells in vitro. Acta 
Pharmacol Sin 36: 1473-1479, 2015.
42. Maiuri Mc, Zalckvar E, Kimchi A and Kroemer G: Self-eating 
and self-killing: crosstalk between autophagy and apoptosis. Nat 
Rev Mol cell Biol 8: 741-752, 2007.
43. Cichoż‑Lach H and Michalak A: Oxidative stress as a crucial 
factor in liver diseases. World J Gastroenterol 20: 8082-8091, 
2014.
44. Jenner P: Oxidative stress in Parkinson's disease. Ann Neurol 53 
(Suppl 3): S26-S38, 2003.
45. Kujoth G, Hiona A, Pugh T, Someya S, Panzer K, Wohlgemuth SE, 
Hofer T, Seo AY, Sullivan R, Jobling WA, et al: Mitochondrial 
dNA mutations, oxidative stress, and apoptosis in mammalian 
aging. Science 309: 481-484, 2005.
46. Radi E, Formichi P, Battisti c and Federico A: Apoptosis and 
oxidative stress in neurodegenerative diseases. J Alzheimers 
dis 42 (Suppl 3): S125-S152, 2014.
47. Osakabe N, Yasuda A, Natsume M, Sanbongi c, Kato Y, Osawa T 
and Yoshikawa T: Rosmarinic acid, a major polyphenolic component 
of Perilla frutescens, reduces lipopolysaccharide (LPS)-induced 
liver injury in d-galactosamine (d-GalN)-sensitized mice. Free 
Radic Biol Med 33: 798-806, 2002.
48. Nowak M, Gaines Gc, Rosenberg J, Minter R, Bahjat FR, 
Rectenwald J, MacKay SL, Edwards cK III and Moldawer LL: 
LPS-induced liver injury in d-galactosamine-sensitized mice 
requires secreted TNF-alpha and the TNF-p55 receptor. Am 
J Physiol Regul Integr comp Physiol 278: R1202-R1209, 2000.
49. Wu YL, Lian LH, Wan Y and Nan JX: Baicalein inhibits 
nuclear factor-κB and apoptosis via c-FLIP and MAPK in 
d-GalN/LPS induced acute liver failure in murine models. 
chem Biol Interact 188: 526-534, 2010.
BAK et al:  PROTEcTIVE EFFEcTS OF hPH AGAINST AcUTE LIVER FAILURE2582
50. chen L, Ren F, Zhang H, Wen T, Piao Z, Zhou L, Zheng S, 
Zhang J, chen Y, Han Y, et al: Inhibition of glycogen synthase 
kinase 3β ameliorates d-GalN/LPS-induced liver injury by 
reducing endoplasmic reticulum stress-triggered apoptosis. PloS 
One 7: e45202, 2012.
51. Wang H, Xu dX, Lv JW, Ning H and Wei W: Melatonin attenu-
ates lipopolysaccharide (LPS)-induced apoptotic liver damage in 
d-galactosamine-sensitized mice. Toxicology 237: 49-57, 2007.
52. Kawakatsu M, Urata Y, Goto S, Ono Y and Li TS: Placental 
extract protects bone marrow-derived stem/progenitor cells 
against radiation injury through anti-inflammatory activity. 
J Radiat Res 54: 268-276, 2012.
53. Park JY, Lee J, Jeong M, Min S, Kim SY, Lee H, Lim Y and 
Park HJ: Effect of Hominis Placenta on cutaneous wound healing 
in normal and diabetic mice. Nutri Res Pract 8: 404-409, 2014.
54. Lee KH, Kim TH, Lee Wc, Kim SH, Lee SY and Lee SM: 
Anti-inflammatory and analgesic effects of human placenta 
extract. Nat Prod Res 25: 1090-1100, 2011.
55. Lee KW, Ji HM, Kim dW, choi SM, Kim S and Yang EJ: 
Effects of Hominis placenta on LPS-induced cell toxicity in BV2 
microglial cells. J Ethnopharmacol 147: 286-292, 2013.
56. Akagi H, Imamura Y, Makita Y, Nakamura H, Hasegawa N, 
Fujiwara SI and Wang PL: Evaluation of collagen type-1 produc-
tion and anti‑inflammatory activities of human placental extracts 
in human gingival fibroblasts. J Hard Tissue Biol 25: 277‑281, 
2016.
57. Watanabe S, Togashi S, Takahashi N and Fukui T: L-tryptophan 
as an antioxidant in human placenta extract. J Nutri Sci Vitaminol 
(Tokyo) 48: 36-39, 2002.
58. Togashi SI, Takahashi N, Iwama M, Watanabe S, Tamagawa K 
and Fukui T: Antioxidative collagen-derived peptides in 
human-placenta extract. Placenta 23: 497-502, 2002.
59. Rozanova S, cherkashina Y, Repina S, Rozanova K and Nardid O: 
Protective effect of placenta extracts against nitrite-induced 
oxidative stress in human erythrocytes. cell Mol Biol Lett 17: 
240-248, 2012.
60. Halliwell B and Gutteridge JM: Free Radicals in Biology and 
Medicine. Oxford University Press, USA, 2015.
61. Wells PG and Winn LM: Biochemical toxicology of chemical 
teratogenesis. crit Rev Biochem Mol Biol 31: 1-40, 1996.
62. Avissar N, Whitin Jc, Allen PZ, Wagner dd, Liegey P and 
cohen HJ: Plasma selenium-dependent glutathione peroxidase. 
cell of origin and secretion. J Biol chem 264: 15850-15855, 1989.
63. Thomas EL, Learn dB, Jefferson MM and Weatherred W: 
Superoxide-dependent oxidation of extracellular reducing agents 
by isolated neutrophils. J Biol chem 263: 2178-2186, 1988.
64. Kankofer M: Antioxidative defence mechanisms against 
reactive oxygen species in bovine retained and not-retained 
placenta: Activity of glutathione peroxidase, glutathione 
transferase, catalase and superoxide dismutase. Placenta 22: 
466-472, 2001.
65. Mochizuki H and Kada T: Restorative effects of human placenta 
extract in X-ray-irradiated mice. J Radiat Res 23: 403-410, 1982.
66. González R, collado JA, Nell S, Briceño J, Tamayo MJ, Fraga E, 
Bernardos A, López-cillero P, Pascussi JM, Rufián S, et al: 
cytoprotective properties of α-tocopherol are related to gene 
regulation in cultured d-galactosamine-treated human hepato-
cytes. Free Radic Biol Med 43: 1439-1452, 2007.
67. Siendones E, Fouad d, Abou-Elella AMKE, Quintero A, 
Barrera P and Muntané J: Role of nitric oxide in d-galactos-
amine-induced cell death and its protection by PGE 1 in cultured 
hepatocytes. Nitric Oxide 8: 133-143, 2003.
68. Mahmoud MF, Hamdan dI, Wink M and El-Shazly AM: 
Hepatoprotective effect of limonin, a natural limonoid from the 
seed of citrus aurantium var. bigaradia, on d-galactosamine- 
induced liver injury in rats. Naunyn-Schmiedebergs Arch 
Pharmacol 387: 251-261, 2014.
69. Wang Y, Li Y, Xie J, Zhang Y, Wang J, Sun X and Zhang H: 
Protective effects of probiotic Lactobacillus casei Zhang 
against endotoxin-and d-galactosamine-induced liver injury 
in rats via anti‑oxidative and anti‑inflammatory capacities. Int 
Immunopharmacol 15: 30-37, 2013.
70. Xia X, Su c, Fu J, Zhang P, Jiang X, Xu d, Hu L, Song E and 
Song Y: Role of α-lipoic acid in LPS/d-GalN induced fulminant 
hepatic failure in mice: Studies on oxidative stress, inflammation 
and apoptosis. Int Immunopharmacol 22: 293-302, 2014.
71. Shin JW, Wang JH, Park HJ, choi MK, Kim HG and Son cG: 
Herbal formula cGX ameliorates LPS/d-galactosamine-induced 
hepatitis. Food chem Toxicol 49: 1329-1334, 2011.
72. Lee HJ, Oh YK, Rhee M, Lim JY, Hwang JY, Park YS, Kwon Y, 
choi KH, Jo I, Park SI, et al: The role of STAT1/IRF-1 on syner-
gistic ROS production and loss of mitochondrial transmembrane 
potential during hepatic cell death induced by LPS/d-GalN. 
J Mol Biol 369: 967-984, 2007.
73. Liu LM, Zhang JX, Luo J, Guo HX, deng H, chen JY and Sun SL: 
A role of cell apoptosis in lipopolysaccharide (LPS)-induced 
nonlethal liver injury in d-galactosamine (d-GalN)-sensitized 
rats. dig dis Sci 53: 1316-1324, 2008.
74. Soriano ME, Nicolosi L and Bernardi P: desensitization of the 
permeability transition pore by cyclosporin A prevents activa-
tion of the mitochondrial apoptotic pathway and liver damage 
by tumor necrosis factor-alpha. J Biol chem 279: 36803-36808, 
2004.
75. Indo HP, davidson M, Yen Hc, Suenaga S, Tomita K, Nishii T, 
Higuchi M, Koga Y, Ozawa T and Majima HJ: Evidence of ROS 
generation by mitochondria in cells with impaired electron trans-
port chain and mitochondrial dNA damage. Mitochondrion 7: 
106-118, 2007.
76. Farombi EO, Shrotriya S, Na HK, Kim SH and Surh YJ: 
curcumin attenuates dimethylnitrosamine-induced liver injury 
in rats through Nrf2-mediated induction of heme oxygenase-1. 
Food chem Toxicol 46: 1279-1287, 2008.
77. Klaassen cd and Reisman SA: Nrf2 the rescue: Effects of the 
antioxidative/electrophilic response on the liver. Toxicol Appl 
Pharmacol 244: 57-65, 2010.
78. Xu W, Shao L, Zhou c, Wang H and Guo J: Upregulation of 
Nrf2 expression in non-alcoholic fatty liver and steatohepatitis. 
Hepatogastroenterology 58: 2077-2080, 2011.
79. Zhao Hd, Zhang F, Shen G, Li YB, Li YH, Jing HR, Ma LF, 
Yao JH and Tian XF: Sulforaphane protects liver injury induced 
by intestinal ischemia reperfusion through Nrf2-ARE pathway. 
World J Gastroenterol 16: 3002-3010, 2010.
80. Pan cW, Pan ZZ, Hu JJ, chen WL, Zhou GY, Lin W, Jin LX 
and Xu cL: Mangiferin alleviates lipopolysaccharide and 
d-galactosamine-induced acute liver injury by activating the 
Nrf2 pathway and inhibiting NLRP3 inflammasome activation. 
Eur J Pharmacol 770: 85-91, 2016.
81. Beyer TA, Xu W, Teupser d, auf dem Keller U, Bugnon P, Hildt E, 
Thiery J, Kan YW and Werner S: Impaired liver regeneration 
in Nrf2 knockout mice: Role of ROS-mediated insulin/IGF-1 
resistance. EMBO J 27: 212-223, 2008.
82. duar te TL, caldas c, Santos AG, Si lva-Gomes S, 
Santos-Gonçalves A, Martins MJ, Porto G and Lopes JM: Genetic 
disruption of NRF2 promotes the development of necroinflam-
mation and liver fibrosis in a mouse model of HFE‑hereditary 
hemochromatosis. Redox Biol 11: 157-169, 2017.
83. Sahin K, Orhan c, Akdemir F, Tuzcu M, Sahin N, Yılmaz I and 
Juturu V: β-cryptoxanthin ameliorates metabolic risk factors 
by regulating NF-κB and Nrf2 pathways in insulin resistance 
induced by high-fat diet in rodents. Food chem Toxicol 107: 
270-279, 2017.
84. choi AM, Ryter SW and Levine B: Autophagy in human health 
and disease. N Engl J Med 368: 651-662, 2013.
85. Uchiyama Y, Shibata M, Koike M, Yoshimura K and Sasaki M: 
Autophagy-physiology and pathophysiology. Histochem cell 
Biol 129: 407-420, 2008.
86. Rautou PE, Mansouri A, Lebrec d, durand F, Valla d and 
Moreau R: Autophagy in liver diseases. J Hepatol 53: 1123-1134, 
2010.
87. Amir M, Zhao E, Fontana L, Rosenberg H, Tanaka K, Gao G and 
czaja MJ: Inhibition of hepatocyte autophagy increases tumor 
necrosis factor-dependent liver injury by promoting caspase-8 
activation. cell death differ 20: 878-887, 2013.
88. donohue TM Jr: Autophagy and ethanol-induced liver injury. 
World J Gastroenterol 15: 1178-1185, 2009.
89. Lin Z, Wu F, Lin S, Pan X, Jin L, Lu T, Shi L, Wang Y, Xu A 
and Li X: Adiponectin protects against acetaminophen-induced 
mitochondrial dysfunction and acute liver injury by promoting 
autophagy in mice. J Hepatol 61: 825-831, 2014.
90. chang cP and Lei HY: Autophagy induction in T cell-independent 
acute hepatitis induced by concanavalin A in ScId/NOd mice. 
Int J Immunopathol Pharmacol 21: 817-826, 2008.
91. Gotoh K, Lu Z, Morita M, Shibata M, Koike M, Waguri S, 
dono K, doki Y, Kominami E, Sugioka A, et al: Participation 
of autophagy in the initiation of graft dysfunction after rat liver 
transplantation. Autophagy 5: 351-360, 2009.
INTERNATIONAL JOURNAL OF MOLEcULAR MEdIcINE  42:  2569-2583,  2018 2583
92. Liu K, Lou J, Wen T, Yin J, Xu B, ding W, Wang A, Liu d, 
Zhang c, chen d and Li N: depending on the stage of hepa-
tosteatosis, p53 causes apoptosis primarily through either 
dRAM-induced autophagy or BAX. Liver Int 33: 1566-1574, 
2013.
93. Maiuri Mc, Malik SA, Morselli E, Kepp O, criollo A, Mouchel PL, 
carnuccio R and Kroemer G: Stimulation of autophagy by the 
p53 target gene Sestrin2. cell cycle 8: 1571-1576, 2009.
94. Salazar M, carracedo A, Salanueva ÍJ, Hernández-Tiedra S, 
Lorente M, Egia A, Vázquez P, Blázquez c, Torres S, 
García S, et al: cannabinoid action induces autophagy-mediated 
cell death through stimulation of ER stress in human glioma 
cells. J clin Invest 119: 1359-1372, 2009.
95. Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Liu X, 
Savaraj N and Lampidis TJ: 2-deoxy-d-glucose activates 
autophagy via endoplasmic reticulum stress rather than ATP 
depletion. cancer chemother Pharmacol 67: 899-910, 2011.
96. Liu K, Shi Y, Guo X, Wang S, Ouyang Y, Hao M, Liu d, Qiao L, 
Li N, Zheng J and chen d: cHOP mediates ASPP2-induced 
autophagic apoptosis in hepatoma cells by releasing Beclin-1 
from Bcl-2 and inducing nuclear translocation of Bcl-2. cell 
death dis 5: e1323, 2014.
97. Tuñón MJ, San-Miguel B, crespo I, Laliena A, Vallejo d, 
Álvarez M, Prieto J and González-Gallego J: Melatonin treat-
ment reduces endoplasmic reticulum stress and modulates the 
unfolded protein response in rabbits with lethal fulminant hepa-
titis of viral origin. J Pineal Res 55: 221-228, 2013.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International (CC BY-NC-ND 4.0) License.
